AIM vs JAGX

AIM ImmunoTech exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a Current Ratio of 0.53, indicating a looming liquidity crisis. The company has suffered a catastrophic price collapse, falling from a 52-week high of $19.74 to $0.52, reflecting a near-total loss of investor confidence. While one analyst maintains a 'strong_buy' rating with a $10 target, this is completely decoupled from the fundamental reality of -53.3% revenue growth and an operating margin of -14,057%. The combination of negative growth, extreme valuation (P/S of 48.15), and failing health metrics suggests a high probability of insolvency or massive dilution.

JAGX exhibits extreme financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.13, indicating negative shareholder equity. The company is facing a severe liquidity crisis with a Quick Ratio of 0.07, suggesting it cannot meet short-term obligations. Despite a positive gross margin, the operating margin is catastrophic at -631.90%, and the stock has collapsed by 92.8% over the last year. The combination of declining revenue and consistent earnings misses points toward a high risk of insolvency.